Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
25.24
-0.30 (-1.17%)
At close: Sep 18, 2026, 4:00 PM EDT
25.24
0.00 (-0.01%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $38.75. The average 1-year stock price forecast is 53.53% higher than the current stock price, while the lowest is $23 (-8.87%) and the highest is $47 (+86.21%).
Price Target: $38.75 (+53.53%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 10 | 10 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Sep 16, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $46 | Buy | Maintains | $46 | +82.25% | Sep 13, 2026 |
| Citi | Citi | Buy Maintains $45 | Buy | Maintains | $45 | +78.29% | Sep 10, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $35 → $40 | Buy | Reiterates | $35 → $40 | +58.48% | Sep 8, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Reiterates $29 | Hold | Reiterates | $29 | +14.90% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
77.89M
from 247.00M
Decreased by -68.47%
Revenue Next Year
50.98M
from 77.89M
Decreased by -34.55%
EPS This Year
-3.53
from -3.29
EPS Next Year
-3.39
from -3.53
EPS and Forward PE are based on non-GAAP adjusted numbers.